Patent for Nano-scale Detection of Ion Channel Function in Lipoparticles
News Feb 21, 2013
The U.S. patent covers the application of Integral Molecular’s Lipoparticle technology for deriving high concentrations of functional ion channels for drug screening, antibody development, and biomedical research. Ion channels are important therapeutic targets for a wide range of human diseases and comprise approximately 15% of existing drug targets. Lipoparticle technology stems from research conducted at the University of Pennsylvania and published in the journals Science, PNAS, and Journal of Virology. US Patent No. 8,377,691 was issued by the U.S. Patent and Trademark Office on February 19, 2013 to Integral Molecular.
“The Lipoparticle technology overcomes many of the challenges of conventional electrophysiological approaches for screening ion channel targets, which have largely been limited to studies with live cells or reconstituted lipid bilayers,” said Dr. Benjamin Doranz, Chief Scientific Officer at Integral Molecular and the inventor of the technology. “Development and validation of the Lipoparticle ion channel technology enabled Integral Molecular to successfully implement high-throughput screening (HTS) campaigns against ion channels, including the identification of novel anti-influenza lead compounds.”
Integral Molecular offers custom-produced Lipoparticles with user-specified membrane proteins, as well as ReadyReceptor® Lipoparticles that contain pre-validated high-concentration membrane protein targets such as GPCRs, transporters, and ion channels. Each lot of Lipoparticles is quality controlled and provided with technical protocols for relevant applications, including antibody screening, biosensor assays, ELISA binding assays, and functional assays. Lipoparticles can be biotinylated or fluorescently labeled to accommodate specialized applications.
Key Cancer-Linked Proteins Thought to be ‘Undruggable’ Until NowNews
A new study published in Nature, conducted by an alliance between industry and academia involving the University of Liverpool, highlights a new approach to targeting key cancer-linked proteins, thought to be ‘undruggable’.READ MORE
Researchers Reveal How Superbug Secretes It’s ToxinNews
Monash University’s Biomedicine Discovery Institute (BDI) researchers have created the first high-resolution structure depicting a crucial part of the ‘superbug’ Pseudomonas aeruginosa. The image identifies the ‘nanomachine’ used by the highly virulent bacteria to secrete toxins, pointing the way for drug design targeting this.READ MORE
Arsenic Trioxide Could Extend Lives of Patients with Aggressive Brain CancerNews
Arsenic trioxide could be a powerful therapy that could extend the lives of certain glioblastoma patients by as much as three to four times the median expectation.READ MORE
Comments | 0 ADD COMMENT
Annual Conference on Antimicrobials and Drug Resistance
Sep 24 - Sep 25, 2018